US-based medical device maker Cernostics has announced that TissueCypher, in a clinical study, has identified high-risk Barrett's esophagus (BE) patients, who are 46 times more likely to have either high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) at the time of biopsy than those patients who scored low-risk with TissueCypher.
The study concluded that TissueCypher, which is a tissue systems pathology test, has been found to better predict the presence of prevalent HGD and EAC in Barrett's esophagus patients than standard pathology testing.
TissueCypher had indicated high-accuracy in detecting the presence of prevalent HGD and EAC, even in biopsies with a pathologic diagnosis of non-dysplastic intestinal metaplasia (non-dysplastic Barrett's Esophagus).
Barrett's Esophagus is a major risk factor for developing HGD and EAC2.
University Of Kansas Medical Center gastroenterologist Dr. Prateek Sharma said: "This study is an important step forward in our ability to more accurately risk-stratify patients with Barrett's Esophagus, which will ultimately lead to improved physician decision making, and more optimal surveillance of patients with Barrett's Esophagus."
TissueCypher diagnostic technology uses digitally scanned images of a biopsy to measure and analyse cellular and molecular changes that precede structural changes within the tissue.
The study was carried out by the University of Pittsburgh, Geisinger Health System, University of Pennsylvania and the Academic Medical Center and evaluated 175 patients with BE, including 30 patients with confirmed HGD or EAC.
It is estimated that 17 million people have confirmed Barrett's esophagus in the US.